Skip to content
Endologix is now Rhevera Medical. Learn more about our evolution.
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Search
News
The latest from Rhevera Medical.
The Latest:
Oct 5
Endologix Rebrands as Rhevera Medical
See Release
All News
All
2026
2025
2024
2023
2022
2021
Mar 20
Endologix Announces 1000 patients treated with the DETOUR® System.
Mar 3
Endologix Appoints Andrew Davis as Chief Commercial Officer
Jan 7
Endologix Announces Leadership Transition
Nov 5
Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session
Jun 18
Endologix Appoints Graham Phillips as Chief Operating Officer
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
